Phenylephrine Hydrochloride

Manufacturer
Alcon Laboratories, Inc. | Alcon Research LLC
Effective date
2025-04-01
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-05-31 21:28:48

Label at a glance#

ProductPhenylephrine Hydrochloride
Active ingredientPhenylephrine Hydrochloride
Label structure18 sections

Indications and uses

Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10%, is indicated to dilate the pupil.

Dosage and administration

In patients 1 year of age or greater, apply one drop of either phenylephrine hydrochloride ophthalmic solution 2.5% or 10% every 3 to 5 minutes to the conjunctival fornix as required up to a maximum of 3 drops per eye per day. In order to obtain a greater degree of mydriasis, phenylephrine hydrochloride ophthalmic solution 10% may be needed. In pediatric patients less than 1 year of age, one drop of phenylephrine ...

Storage and handling

Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% is supplied as a sterile, aqueous, topical ophthalmic solution in an opaque, white low density polyethylene (LDPE) bottle with a natural LDPE dropper tip and red cap in the following sizes: NDC 0065-0349-05         2 mL in 4 mL bottle NDC 0065-0349-04         15 mL in 15 mL bottle Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is supplied as a ste...

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10%, is indicated to dilate the pupil.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

2.1 General Dosing Recommendations

SPL UNCLASSIFIED SECTION

In patients 1 year of age or greater, apply one drop of either phenylephrine hydrochloride ophthalmic solution 2.5% or 10% every 3 to 5 minutes to the conjunctival fornix as required up to a maximum of 3 drops per eye per day.

In order to obtain a greater degree of mydriasis, phenylephrine hydrochloride ophthalmic solution 10% may be needed.

2.2 Dosing in Pediatric Patients Less Than 1 Year of Age

SPL UNCLASSIFIED SECTION

In pediatric patients less than 1 year of age, one drop of phenylephrine hydrochloride ophthalmic solution 2.5% should be instilled at 3 to 5 minute intervals up to a maximum of 3 drops per eye.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

Phenylephrine hydrochloride ophthalmic solution, USP 2.5% is a clear, colorless to yellow, sterile topical ophthalmic solution containing phenylephrine hydrochloride 2.5%: each mL contains 25 mg of phenylephrine hydrochloride.

Phenylephrine hydrochloride ophthalmic solution, USP 10% is a clear, colorless to yellow, sterile topical ophthalmic solution containing phenylephrine hydrochloride 10%.: each mL contains 100 mg of phenylephrine hydrochloride.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

4.1 Cardiac and Endocrine Disease

SPL UNCLASSIFIED SECTION

Phenylephrine hydrochloride ophthalmic solution 10% is contraindicated in patients with hypertension or thyrotoxicosis. Phenylephrine hydrochloride ophthalmic solution 2.5% should be used in these patients.

4.2 Pediatric Patients Less Than 1 Year of Age

SPL UNCLASSIFIED SECTION

Phenylephrine hydrochloride ophthalmic solution 10% is contraindicated in pediatric patients less than 1 year of age due to the increased risk of systemic toxicity. Phenylephrine hydrochloride ophthalmic solution 2.5% should be used in these patients [See Dosage and Administration (2.2)].

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Topical Ophthalmic Use Only

SPL UNCLASSIFIED SECTION

Phenylephrine hydrochloride ophthalmic solution 2.5% and 10% is not indicated for injection.

5.2 Cardiovascular Reactions

SPL UNCLASSIFIED SECTION

There have been reports of serious cardiovascular reactions, including ventricular arrhythmias and myocardial infarctions, in patients using phenylephrine 10%. These episodes, some fatal, have usually occurred in patients with pre-existing cardiovascular diseases. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients.

5.3 Elevation of Blood Pressure

SPL UNCLASSIFIED SECTION

A significant elevation in blood pressure is not common but has been reported following conjunctival instillation of recommended doses of phenylephrine 10%. The risk is less with phenylephrine 2.5%. Caution should be exercised with the use of phenylephrine 10% in pediatric patients less than 5 years of age and patients with hyperthyroidism, or cardiovascular disease. The post-treatment blood pressure of patients with cardiac and endocrine diseases and any patients who develop symptoms should be carefully monitored.

5.4 Rebound Miosis

SPL UNCLASSIFIED SECTION

Rebound miosis has been reported one day after receiving phenylephrine hydrochloride ophthalmic solution, and re-instillation of the drug produced a lesser mydriatic effect.

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following serious adverse reactions are described below and elsewhere in the labeling:

  • Cardiovascular Effects [See Warnings and Precautions (5.2 )]
  • Elevation in Blood Pressure [See Warnings and Precautions (5.3 )]

The following adverse reactions have been identified following use of phenylephrine hydrochloride ophthalmic solution. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

6.1 Ocular Adverse Reactions

SPL UNCLASSIFIED SECTION

Eye pain and stinging on instillation, temporary blurred vision and photophobia, and conjunctival sensitization may occur.

6.2 Systemic Adverse Reactions

SPL UNCLASSIFIED SECTION

A marked increase in blood pressure has been reported particularly, but not limited to low weight premature neonates, infants and hypertensive patients.

Cardiovascular effects which have been seen primarily in hypertensive patients following topical ocular use of phenylephrine hydrochloride ophthalmic solution 10% include marked increase in blood pressure, syncope, myocardial infarction, tachycardia, arrhythmia and subarachnoid hemorrhage [See Warnings and Precautions (5.2 and 5.3 )].

7 DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

7.1 Agents That May Exaggerate Pressor Responses

SPL UNCLASSIFIED SECTION

Concomitant use of phenylephrine and atropine may enhance the pressor effects and induce tachycardia in some patients. Phenylephrine may potentiate the cardiovascular depressant effects of some inhalation anesthetic agents.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Animal reproduction studies have not been conducted with topical phenylephrine. It is also not known whether phenylephrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Phenylephrine hydrochloride should be given to a pregnant woman only if clearly needed.

8.3 Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human breast milk. Because many drugs are excreted in human milk, caution should be exercised when phenylephrine hydrochloride ophthalmic solution 2.5% and 10% is administered to a nursing woman.

8.4 Pediatric Use

PEDIATRIC USE SECTION

Phenylephrine hydrochloride ophthalmic solution 10% is contraindicated in pediatric patients less than 1 year of age [See Contraindications (4.2)].

8.5 Geriatric Use

GERIATRIC USE SECTION

No overall differences in safety and effectiveness have been observed between elderly and younger adult patients.

10 OVERDOSAGE

OVERDOSAGE SECTION

Overdosage of phenylephrine may cause a rapid rise in blood pressure. It may also cause headache, anxiety, nausea, and vomiting, and ventricular arrhythmias. Prompt injection of a rapidly acting alpha-adrenergic blocking agent such as phentolamine has been recommended.

11 DESCRIPTION

DESCRIPTION SECTION

Phenylephrine Hydrochloride Ophthalmic Solution, USP is a sterile, clear, colorless to yellow, topical α-adrenergic agonist for ophthalmic use. The active ingredient is represented by the chemical structure

Chemical Structure
Chemical Structure

Chemical Name: (R)-3-hydroxy-α[(methylamino)methyl]benzenemethanol hydrochloride.

Molecular Formula: C9H13NO2.HCl

Molecular Weight: 203.67 g/mol

Each mL of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% contains: ACTIVE: Phenylephrine Hydrochloride 25 mg (2.5%); INACTIVES: Sodium Phosphate Monobasic, Sodium Phosphate Dibasic, Water for Injection. Phosphoric Acid and/or Sodium Hydroxide may be added to adjust pH (4.0 to 7.5). The solution has a tonicity of 340 mOsm/kg; PRESERVATIVE: Benzalkonium Chloride 0.1 mg (0.01%).

Each mL of Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% contains: ACTIVE: Phenylephrine Hydrochloride 100 mg (10%); INACTIVES: Sodium Phosphate Monobasic, Sodium Phosphate Dibasic, Water for Injection. Phosphoric Acid and/or Sodium Hydroxide may be added to adjust pH (4.0 to 7.5). The solution has a tonicity of 985 mOsm/kg; PRESERVATIVE: Benzalkonium Chloride 0.1 mg (0.01%).

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

Phenylephrine hydrochloride is an α-1 adrenergic agonist drug that is used in ophthalmology mainly for its mydriatic effect. After topical application to the conjunctiva, phenylephrine acts directly on α-adrenergic receptors in the eye, producing contraction of the dilator muscle of the pupil and constriction of the arterioles in the conjunctiva.

12.2 Pharmacodynamics

PHARMACODYNAMICS SECTION

Maximal mydriasis occurs in 20 to 90 minutes with recovery after 3 to 8 hours.

Systemic absorption of sufficient quantities of phenylephrine may lead to systemic α-adrenergic effects, such as rise in blood pressure which may be accompanied by a reflex atropine-sensitive bradycardia.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

The systemic exposure following topical administration of phenylephrine hydrochloride ophthalmic solution has not been studied. A higher systemic absorption is expected for the 10% solution than the 2.5% solution and when the corneal barrier function is compromised.

14 CLINICAL STUDIES

CLINICAL STUDIES SECTION

Pupillary dilation following topical administration of phenylephrine hydrochloride ophthalmic solution has been demonstrated in controlled clinical studies in adults and pediatric patients with different levels of iris pigmentation. Pupil movement is generally seen within 15 minutes, maximal mydriasis between 20 to 90 minutes and recovery after 3 to 8 hours. Darker irides tend to dilate slower than lighter irides.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% is supplied as a sterile, aqueous, topical ophthalmic solution in an opaque, white low density polyethylene (LDPE) bottle with a natural LDPE dropper tip and red cap in the following sizes:

NDC 0065-0349-05         2 mL in 4 mL bottle
NDC 0065-0349-04         15 mL in 15 mL bottle

Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is supplied as a sterile, aqueous, topical ophthalmic solution in an opaque, white low density polyethylene (LDPE) bottle with a natural LDPE dropper tip and red cap in the following sizes:

NDC 0065-0343-02         5 mL in 8 mL bottle

After opening, Phenylephrine Hydrochloride Ophthalmic Solution, USP can be used until the expiration date on the bottle.

STORAGE AND HANDLING SECTION

Storage: Store at 20°C to 25°C (68°F to 77°F).

Keep container tightly closed.

Protect from light and excessive heat.

Do not use if solution is brown or contains precipitate.

17. PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Advise patients not to touch the dropper tip to any surface as this may contaminate the solution. Inform patients that they may experience sensitivity to light and should protect their eyes in bright illumination while their pupils are dilated.

Distributed by: ALCON LABORATORIES, INC.
Fort Worth, Texas 76134 U.S.A.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Container Label:

Phenylephrine Hydrochloride
Ophthalmic Solution, USP


2.5%

Sterile
Rx only


Alcon

2mL

NDC 0065-0349-05
Each mL contains: Active:
Phenylephrine Hydrochloride (2.5%)
Storage: Store at 20ºC-25ºC (68ºF-77ºF).
Dosage: see Prescribing Information
ALCON LABORATORIES, INC.
Fort Worth, Texas 76134 USA

LOT:               EXP.:

300066881-0924

2mL label
2mL label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Carton Label:

Rx only
Sterile


NDC 0065-0349-05

Phenylephrine
Hydrochloride
Ophthalmic
Solution, USP 2.5%


FOR TOPICAL APPLICATION IN THE EYE

2mL

Alcon

Each mL contains:
Active: Phenylephrine
Hydrochloride 25 mg (2.5%);
Inactives: Sodium Phosphate
Dibasic, Sodium Phosphate
Monobasic, Sodium Hydroxide
and/or Phosphoric Acid may be
added to adjust pH (4.0 to 7.5)
and Water for Injection q.s.;
Preservative: Benzalkonium
Chloride 0.1 mg (0.01%).

Dosage: see Prescribing
Information.
Storage: Store at 20ºC to 25ºC
(68ºF to 77ºF). Keep tightly
closed. Protect from light and
excessive heat.
Do not use if solution is
brown or contains a
precipitate.


KEEP OUT OF REACH OF
CHILDREN.

DO NOT USE IF IMPRINTED
SEAL IS BROKEN OR MISSING.

ALCON LABORATORIES, INC.
6201 South Freeway
Fort Worth, Texas 76134 USA
1-800-757-9195
alcon.medinfor@alcon.com
Printed in USA

300066873-0924

SN:
LOT:
EXP.:
GTIN:
 00300650349055

2mL carton
2mL carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Container Label:

NDC 0065-0349-04

15mL

300066880-0924

15mL label
15mL label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Carton Label:

NDC 0065-0349-04

15mL

300066872-0924

SN:
LOT:
EXP.:
GTIN:
 00300650349048

15mL carton
15mL carton

Principal Display Panel Text for Container Label:

NDC 0065-0343-02

Phenylephrine
Hydrochloride
Ophthalmic
Solution, USP


10%

FOR TOPICAL APPLICATION
IN THE EYE


Sterile Rx
only 


Alcon

5 mL

Each mL contains: Active:
Phenylephrine Hydrochloride (10%);
Inactives: Sodium
Phosphate Dibasic, Sodium
Phosphate Monobasic, Sodium
Hydroxide and/or Phosphoric Acid
may be added to adjust pH (4.0 to
7.5) and Water for Injection q.s.;
Preservative: Benzalkonium
Chloride 0.1 mg (0.01%).


Dosage: see Prescribing
Information.
Storage: Store at 20ºC to 25ºC
(68ºF to 77ºF). Keep container
tightly closed. Do not use if
solution is brown or contains a
precipitate.
DO NOT USE IF IMPRINTED
SEAL IS BROKEN OR MISSING.


ALCON LABORATORIES, INC.
Fort Worth, Texas 76134 USA

LOT:                        EXP.:

30006 7943-0225

5mL label
5mL label

Principal Display Panel Text for Carton Label:

NDC 0065-343-02

KEEP OUT OF REACH OF
CHILDREN


ALCON LABORATORIES, INC.
6201 South Freeway
Fort Worth, Texas 76134 USA
1-800-757-9195
alcon.medinfor@alcon.com
Printed in USA

SN:
LOT:
EXP.:
GTIN: 00300650343022

300067876-0225

5mL carton
5mL carton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1234571phenylephrine HCl 10 % Ophthalmic SolutionPSN3
1234579phenylephrine HCl 2.5 % Ophthalmic SolutionPSN3
1234571phenylephrine hydrochloride 100 MG/ML Ophthalmic SolutionSCD3
1234579phenylephrine hydrochloride 25 MG/ML Ophthalmic SolutionSCD3
1234571phenylephrine hydrochloride 10 % Ophthalmic SolutionSY3
1234579phenylephrine hydrochloride 2.5 % Ophthalmic SolutionSY3

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
PHENYLEPHRINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
726062af-1135-4707-a1d7-57256991bbf9Product name220250226
19c71a3d-ed9c-166b-a7e5-38c250c35631Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0065-0343-02Phenylephrine Hydrochloride1 in 1 CARTONSOLUTION/ DROPS13
0065-0343-02Phenylephrine Hydrochloride5 mL in 1 BOTTLE, DROPPERSOLUTION/ DROPS53
0065-0349-04Phenylephrine Hydrochloride15 mL in 1 BOTTLE, DROPPERSOLUTION/ DROPS153
0065-0349-04Phenylephrine Hydrochloride1 in 1 CARTONSOLUTION/ DROPS13
0065-0349-05Phenylephrine Hydrochloride1 in 1 CARTONSOLUTION/ DROPS13
0065-0349-05Phenylephrine Hydrochloride2 mL in 1 BOTTLE, DROPPERSOLUTION/ DROPS23

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0065-0343PHENYLEPHRINE HYDROCHLORIDE SOLUTION/ DROPS [ALCON LABORATORIES, INC.]3Current NDC, 2 package rows20250403_cacbb3fd-1c03-4523-a1bf-0ccc4be102ef.zip
0065-0349PHENYLEPHRINE HYDROCHLORIDE SOLUTION/ DROPS [ALCON LABORATORIES, INC.]3Current NDC, 4 package rows20250403_cacbb3fd-1c03-4523-a1bf-0ccc4be102ef.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0065-0349-04ML - Milliliter0065-0349be4d46b5-2856-41bf-8e13-5f85ceadbaa012025-03-04
0065-0349-05ML - Milliliter0065-03494e1d3d87-e63b-400c-aefd-6ddc3eacdcf312025-03-04
0065-0343-02ML - Milliliter0065-03430f40919e-808c-4082-a4f0-f16d1038630312025-11-13

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0065-03490065-0349-05, 0065-0349-04
0065-03430065-0343-02

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 14 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N207926-001PHENYLEPHRINE HYDROCHLORIDEPHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-15
N207926-002PHENYLEPHRINE HYDROCHLORIDEPHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-15

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 2 matching rows.

Application-product, TE code table
Application-productTE code
N207926-001AT
N207926-002AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 86 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-1584e616aacf4f…
2026-09-14 22:38:342026-08N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-1584e616aacf4f…
2026-08-18 06:07:402026-07N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-15caaa826d4ba7…
2026-08-18 06:07:402026-07N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-15caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-15011fe1cb6892…
2026-02-19 14:30 UTC2026-02N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-15011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-1531067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-1531067a03dcf5…
2025-08-23 18:47 UTC2025-08N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-156a471c1ec25d…
2025-08-23 18:47 UTC2025-08N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-156a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-15fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-15fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-15b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-15b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-1503ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-1503ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-152680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-152680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-155bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-155bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-15d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-15d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-15d06236e962d9…
2024-10-29 15:01 UTC2024-10N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-15d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-1579d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-1579d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-15301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-15301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-151e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-151e350fbaab3a…
2024-05-31 18:47 UTC2024-05N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-158072bd15b7f6…
2024-05-31 18:47 UTC2024-05N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD2015-01-158072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD, RS2015-01-155c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD, RS2015-01-155c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD, RS2015-01-155d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD, RS2015-01-155d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD, RS2015-01-154b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD, RS2015-01-154b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N207926-001PHENYLEPHRINE HYDROCHLORIDE2.5%SOLUTION/DROPS / OPHTHALMICATRLD, RS2015-01-1574a2ff9319b5…
2019-12-13 00:20 UTC2019-12N207926-002PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRLD, RS2015-01-1574a2ff9319b5…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 3 · 86 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08N207926-001AT184e616aacf4f…
2026-09-14 22:38:342026-08N207926-002AT184e616aacf4f…
2026-08-18 06:07:402026-07N207926-001AT1caaa826d4ba7…
2026-08-18 06:07:402026-07N207926-002AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N207926-001AT1011fe1cb6892…
2026-02-19 14:30 UTC2026-02N207926-002AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N207926-001AT131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N207926-002AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08N207926-001AT16a471c1ec25d…
2025-08-23 18:47 UTC2025-08N207926-002AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N207926-001AT1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N207926-002AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N207926-001AT1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N207926-002AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N207926-001AT103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N207926-002AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N207926-001AT12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N207926-002AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N207926-001AT15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N207926-002AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N207926-001AT1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N207926-002AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N207926-001AT1d06236e962d9…
2024-10-29 15:01 UTC2024-10N207926-002AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N207926-001AT179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N207926-002AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N207926-001AT1301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N207926-002AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N207926-001AT11e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N207926-002AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N207926-001AT18072bd15b7f6…
2024-05-31 18:47 UTC2024-05N207926-002AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N207926-001AT15c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N207926-002AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N207926-001AT15d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N207926-002AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N207926-001AT14b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N207926-002AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N207926-001AT174a2ff9319b5…
2019-12-13 00:20 UTC2019-12N207926-002AT174a2ff9319b5…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Phenylephrine HydrochloridePHENYLEPHRINE HYDROCHLORIDEAlcon Laboratories, Inc.cacbb3fd-1c03-4523-a1bf-0ccc4be102ef2025-04-01Warnings, Adverse reactionsExact identifier
ndc (package): 0065-0343-02
ndc (package): 0065-0349-05
ndc (package): 0065-0349-04
ndc (product): 0065-0343
ndc (product): 0065-0349
ndc11 (package): 00065034905
ndc11 (package): 00065034904
ndc11 (package): 00065034302
spl id: c9ffa382-0391-4947-9638-dd7d648a6e38
spl set id: cacbb3fd-1c03-4523-a1bf-0ccc4be102ef

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.